CD19 and acute lymphoblastic leukemia: This approach has been demonstrated in a safety assessment clinical trial that involved 30 children and adult patients with relapsed and refractory acute lymphoblastic leukemia (ALL).296 In these patients, autologous T cells were transduced with lentiviral vectors carrying a transgene to express a CAR that binds CD19.